VEGFA and cancer: The partial resistance of MPE to TKI treatment suggests intrinsic factors affecting the therapeutic efficacy, such as activation of VEGF signaling, enrichment of putative cancer stem cells in MPE 21, and primary resistance by cooccurring genetic alterations such as Kras22.